Narula J, Bennett L E, DiSalvo T, Hosenpud J D, Semigran M J, Dec G W
Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Transplantation. 1997 Mar 27;63(6):861-7. doi: 10.1097/00007890-199703270-00012.
In patients awaiting heart transplantation, end-stage disease of a second organ may occasionally require consideration of simultaneous multiorgan transplantation. Outcome statistics in multiorgan transplant recipients are needed to define optimal utilization of scarce donor resources. Incidence of cardiac allograft rejection, actuarial recipient survival, and cardiac allograft rejection-free survival were evaluated in 82 recipients of 84 simultaneous heart and kidney transplants. Twenty-three of the 82 dual-organ recipients have died with 1, 6, 12, and 24-month actuarial survival rates of 92%, 79%, 76%, and 67%, respectively. The actuarial survival rates in the heart-kidney recipients were similar to those observed in 14,340 isolated heart recipients (United Network for Organ Sharing Scientific Registry) during the same period (92%, 86%, 83%, and 79%, respectively; P=0.20). Clinical data on all episodes of treated rejection in either organ and on immunosuppressive regimens were available on 56 patients; 48% of these patients have had no rejection in either organ, 27% experienced heart rejection alone, 14% experienced kidney rejection alone, and 11% had both heart and kidney allograft rejection. Heart allograft rejection was less common in heart-kidney recipients, as compared with isolated heart transplant recipients; 0, 1, and > or = 2 treated cardiac allograft rejection episodes occurred in 63%, 20%, and 18% of heart-kidney recipients compared with 46%, 27%, and 28% of 911 isolated heart recipients reported by Transplant Cardiologists' Research Database (P=0.02). The rejection-free survival rates at 1, 3, and 6 months were 88%, 74%, and 71% in the double-organ recipients, as compared with 66%, 44%, and 39%, respectively, in the single-organ recipients. Compared with isolated heart transplantation, combined heart-kidney transplantation does not adversely affect intermediate survival and results in a lower incidence of treated cardiac allograft rejection. The findings suggest that combined heart-kidney transplantation may be an acceptable option in a small subset of potential heart transplant recipients with severe renal dysfunction.
在等待心脏移植的患者中,第二个器官的终末期疾病偶尔可能需要考虑同时进行多器官移植。需要多器官移植受者的结果统计数据来确定稀缺供体资源的最佳利用方式。对84例同期心脏和肾脏联合移植的82例受者进行了心脏移植排斥反应的发生率、受者实际生存率和无心脏移植排斥反应生存率的评估。82例双器官受者中有23例死亡,1个月、6个月、12个月和24个月的实际生存率分别为92%、79%、76%和67%。同期,心脏-肾脏联合移植受者的实际生存率与14340例单纯心脏移植受者(器官共享联合网络科学登记处)的生存率相似(分别为92%、86%、83%和79%;P=0.20)。56例患者可获得任一器官所有治疗性排斥反应发作的临床数据以及免疫抑制方案;这些患者中48%在任一器官均未发生排斥反应,27%仅发生心脏排斥反应,14%仅发生肾脏排斥反应,11%同时发生心脏和肾脏移植排斥反应。与单纯心脏移植受者相比,心脏-肾脏联合移植受者的心脏移植排斥反应较少见;心脏-肾脏联合移植受者中63%、20%和≥2次治疗性心脏移植排斥反应发作的发生率分别为0、1次和≥2次,而移植心脏病学家研究数据库报告的911例单纯心脏移植受者中这一比例分别为46%、27%和28%(P=0.02)。双器官受者1个月、3个月和6个月的无排斥反应生存率分别为88%、74%和71%,而单器官受者分别为66%、44%和39%。与单纯心脏移植相比,心脏-肾脏联合移植不会对中期生存率产生不利影响,且治疗性心脏移植排斥反应的发生率较低。这些发现表明,心脏-肾脏联合移植可能是一小部分潜在心脏移植受者伴有严重肾功能不全时的一个可接受的选择。